Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Electrophysiology

Background:

• Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease.
• Emerging evidence suggests a potential link between high Lp(a) levels and atrial fibrillation (AF).
• Understanding the indirect mechanisms of Lp(a) in AF pathogenesis is crucial for risk stratification and treatment.

Purpose of the Study:

• To review the indirect pathways through which elevated Lp(a) may contribute to the development of atrial fibrillation (AF).
• To evaluate the efficacy of current and emerging therapies in reducing Lp(a) levels and cardiovascular risk.
• To highlight research gaps and future directions for investigating the Lp(a)-AF association.

Main Methods:

• Literature review of studies investigating lipoprotein(a) [Lp(a)] and its association with cardiovascular diseases and atrial fibrillation (AF).
• Analysis of proposed indirect mechanisms including proatherogenic, prothrombotic, and proinflammatory pathways.
• Assessment of the impact of various lipid-lowering therapies on Lp(a) levels and cardiovascular outcomes.

Main Results:

• Lipoprotein(a) [Lp(a)] influences AF indirectly via proatherogenic, prothrombotic, and proinflammatory pathways.
• Standard lipid-lowering therapies show limited impact on Lp(a) levels.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and lipoprotein apheresis are effective in reducing both Lp(a) and cardiovascular events.

Conclusions:

• Targeting elevated lipoprotein(a) [Lp(a)] may offer a novel strategy for preventing atrial fibrillation (AF) and cardiovascular events.
• PCSK9 inhibitors and lipoprotein apheresis demonstrate significant potential in managing Lp(a)-associated risks.
• Further large-scale, diverse population studies are necessary to fully elucidate the Lp(a)-AF relationship and guide therapeutic development.